Company news
Marvel Biosciences Corp news in 2026
Marvel Biosciences Corp's news releases, calls and decks from 2026, newest first.
CEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for Autism
October 21, 2026
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
October 19, 2026
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
October 8, 2026
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
September 29, 2026
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
September 17, 2026
Marvel Biosciences Announces Extension to Closing Date of Private Placement
September 9, 2026
Marvel Biosciences Expands Private Placement to Quebec
August 19, 2026
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
August 5, 2026
Marvel Biosciences Announces Private Placement for up to $3.0 Million
July 16, 2026
New Autism Research to be Presented at European Purine Scientific Meeting
June 26, 2026
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
June 8, 2026
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026
Marvel Biosciences Announces Closing of Convertible Debenture Offering
April 17, 2026
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
April 13, 2026
Marvel Biosciences Announces Proposed Convertible Debenture Offering
April 8, 2026
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
March 25, 2026
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
March 18, 2026
Marvel Biosciences Sponsors Scientific Meeting on Purines
March 4, 2026
Marvel Biosciences Announces Grant of Deferred Share Units
February 18, 2026
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
February 18, 2026
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
February 3, 2026
Decks in 2026
- Investor Presentation (February 2026)
Investor deck · 15 slides · February 2026